Article
EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2009
Varella-Garcia Marileila, Mitsudomi Tetsuya, Yatabe Yashushi, Kosaka Takayuki, Nakajima Eiji, Xavier Ana Carolina, Skokan Margaret, Zeng Chan, Franklin Wilbur A, Bunn Paul A, Hirsch Fred R
Abstract excerpt
BACKGROUND: Sensitivity to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and frequency of activation mutations in EGFR is lower in Caucasian than Asian non small-cell lung cancer (NSCLC) patients. Increased EGFR gene copy numbers evaluated by fluorescence in situ hybridization (FISH) has been reported as predictor of clinical benefit from EGFR-TKIs in Caucasian NSCLC patients. This...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.